← Therapy pipeline
Investigational · Obesity development

Aleniglipron

GSBR-1290 · Structure Therapeutics

Once-daily oral small-molecule GLP-1 receptor agonist.

GLP-1
Other study areas
Type 2 diabetesBody composition
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorStructure Therapeutics
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Selected study results

ACCESS · primary Phase 2b publicationMean body-weight change · primary endpointBody weight decreased 12.1% · 36 weeks · Phase 2b
Phase 2b · Oral · Peer-reviewed numerical results

Mean body-weight change · primary endpoint · 36 weeks

Study focus: Weight management

Aleniglipron 120 mg
12.1%
Placebo
0.8%

Adults with obesity or overweight and a weight-related comorbidity · 45, 90 or 120 mg once daily · Trial N=230 · Efficacy estimand; least-squares mean change. Results & methods ↗ · Publication ↗

Same ACCESS trial · week-36 efficacy estimand
Daily doseWeight changePlacebo-adjusted difference
45 mg−9.0%−8.2 pp
90 mg−10.7%−9.8 pp
120 mg−12.1%−11.3 pp
Placebo−0.8%—

Placebo-adjusted differences are percentage points, not total active-arm weight reduction. Confidence intervals and P values were not adjusted for multiplicity. The separate 44-week ACCESS II sponsor estimate is shown below.

ACCESS IIPlacebo-adjusted weight-loss differencePlacebo-adjusted weight-loss difference: −16.3 percentage points · 44 weeks · Phase 2
Phase 2 · Oral · Sponsor-reported numerical results

Placebo-adjusted weight-loss difference · 44 weeks

Study focus: Weight management

Placebo-adjusted difference, not the total change in the active arm.

Difference versus placebo
16.3 percentage points

Adults in the ACCESS II obesity study · 180 mg once daily · N not included in this summary · Sponsor topline; placebo-adjusted estimate. Results & methods ↗

Placebo-adjusted percentage-point difference, not total loss from baseline. Sample size and full analysis details are not reproduced in this summary.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Oral tabletOnce daily
Phase 3Initiated
Milestone → next

Latest: Phase 3 ACCOMPLISH chronic weight-management program initiated August 2026.

Next: ACCOMPLISH outcomes; ACCESS follow-up.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

ACCOMPLISH-1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and at least one weight-related comorbidity; registrational weight-management study.

Phase 3

ACCOMPLISH-2

Weight management with type 2 diabetes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight and type 2 diabetes; registrational weight-management study.

Phase 2 studies2 records

Phase 2b

ACCESS

Weight management
Study: CompletedResults: Peer-reviewed 36-week primary results shown aboveStatus reviewed November 2026

Adults with obesity or overweight and at least one weight-related comorbidity; published dose-ranging study.

Phase 2

ACCESS II

Weight management
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

Higher-dose study in adults with obesity or overweight and at least one weight-related comorbidity.

Related conditions and outcomes

Phase 2 studies1 record

Phase 2

Body-composition study

Body composition / lean mass
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Evaluates aleniglipron-associated changes in body composition in adults with obesity.